Brevan Howard Capital Management LP Has $1.15 Million Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Brevan Howard Capital Management LP grew its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 210.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,539 shares of the company's stock after acquiring an additional 30,213 shares during the quarter. Brevan Howard Capital Management LP owned about 0.05% of IDEAYA Biosciences worth $1,145,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. R Squared Ltd acquired a new position in IDEAYA Biosciences during the 4th quarter worth approximately $35,000. Daiwa Securities Group Inc. boosted its stake in shares of IDEAYA Biosciences by 44.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock valued at $72,000 after purchasing an additional 853 shares during the period. KBC Group NV grew its holdings in IDEAYA Biosciences by 84.6% during the 4th quarter. KBC Group NV now owns 4,197 shares of the company's stock valued at $108,000 after purchasing an additional 1,923 shares in the last quarter. Cibc World Markets Corp acquired a new position in IDEAYA Biosciences in the 4th quarter worth $203,000. Finally, Mariner LLC grew its stake in shares of IDEAYA Biosciences by 9.8% during the fourth quarter. Mariner LLC now owns 9,775 shares of the company's stock valued at $251,000 after acquiring an additional 869 shares in the last quarter. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

IDEAYA Biosciences Price Performance

NASDAQ IDYA traded down $0.70 on Tuesday, hitting $17.65. 167,198 shares of the company were exchanged, compared to its average volume of 988,618. The company's 50 day moving average price is $17.72 and its 200-day moving average price is $22.51. IDEAYA Biosciences, Inc. has a twelve month low of $13.45 and a twelve month high of $44.42. The firm has a market capitalization of $1.55 billion, a P/E ratio of -5.35 and a beta of 0.26.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter in the previous year, the firm earned ($0.53) EPS. As a group, equities analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Stephens reissued an "overweight" rating and issued a $50.00 price objective on shares of IDEAYA Biosciences in a report on Friday, February 14th. Royal Bank of Canada reissued an "outperform" rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $53.58.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.